Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.

Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.

Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.

Abstract: The present invention provides methods for treating alcohol dependence and preventing relapse in subjects in protracted alcohol abstinence. Also provided are methods for treating subjects suffering from cannabis dependence. Typically, these methods entail administering to the subjects in need of treatment a therapeutically effective amount of gabapentin, an analog of gabapentin, or pharmaceutically acceptable salt thereof.

Abstract: A method for treating or preventing a host mammal that exhibits aversive signs and symptoms present during protracted abstinence or extended discontinuation syndromes as seen after cessation of compulsive activity, behaviors, or substance use is disclosed. That method comprises administering to a host mammal in need a pharmaceutical composition containing an aversive sign and symptom lessening amount a compound of Formula I or a pharmaceutically acceptable salt thereof dissolved or dispersed in a physiologically acceptable diluent, and repeating the administration as needed, wherein W, X, Y and Z, R1 and Ar are defined within. Data are provided in rats as host mammals using behavioral models dependent on the CRF1 system: defensive burying, alcohol dependence, cocaine dependence and nicotine dependence. A contemplated method also is useful for inhibiting relapse of such a behavior.

Abstract: The present invention provides a device for flushing a cavitation plate water intake outboard motor. The invention includes as coupling for attaching the device to a water source such as a hose, a flow passage for directing water through the device and into the outboard motor, and an attachment portion for attaching the device to the outboard motor.

Abstract: The present invention provides a device for flushing a cavitation plate water intake outboard motor. The invention includes as coupling for attaching the device to a water source such as a hose, a flow passage for directing water through the device and into the outboard motor, and an attachment portion for attaching the device to the outboard motor.

Abstract: In accordance with the present invention, there are provided CRF overproducing transgenic mice which exhibit endocrine abnormalities involving the hypothalamic-pituitary-adrenal axis, such as elevated plasma levels of ACTH and glucocorticoids. The transgenic mice of the present invention represent a genetic model of CRF overproduction, providing a valuable tool for investigating the long term effects of CRF excess and dysregulation in the central nervous system.

Abstract: A mobile laser surgical center includes a truck body in which the surgical center is housed and a truck cab which transports the surgical center from one location to another. The surgical center includes a laser, a control for the laser and a patient seat. The truck body includes a floor, side walls, and a top. The laser is secured to the floor such that substantially no realignment of the laser is needed when the center is transported between locations. The truck body is also stabilized so that the truck body floor will be maintained in a level condition during a surgical procedure.